Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Completed 3Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

CNS 5

Conditions

Glioblastoma 5Glioma 4Brain Neoplasms 4Recurrence 1

Interventions

pembrolizumab 1251Specimen Handling 867Carboplatin 816Magnetic Resonance Spectroscopy 803Cyclophosphamide 794Cisplatin 715Nivolumab 646Paclitaxel 623Radiotherapy 564Gemcitabine 562Biopsy 529Bevacizumab 468Dexamethasone 433fludarabine 404Docetaxel 370venetoclax 365Oxaliplatin 362Fluorouracil 352Capecitabine 350atezolizumab 341Rituximab 326durvalumab 326Doxorubicin 313Radiosurgery 305Pemetrexed 302Drug Therapy 294Standard of Care 292Ipilimumab 289Etoposide 279Radiation 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Dianhydrogalactitol × 1 year × Clear all
NCT03970447 2026-06-03

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting
2,250 enrolled
CNS

Glioblastoma, Recurrence

NCT03050736 2025-09-04

Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression

Kintara Therapeutics, Inc.

Phase 2 Completed
29 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma

NCT03149575 2025-09-04

STAR-3

Kintara Therapeutics, Inc.

Phase 3 Terminated
2 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma

NCT01478178 2025-08-29

Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma

Kintara Therapeutics, Inc.

Phase 1/2 Completed
55 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma

NCT02717962 2025-08-29

Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting

Kintara Therapeutics, Inc.

Phase 2 Completed
118 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡